Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Computer Assisted Quantitative Image Analysis as a Pathway to Identification of Combined Pulmonary Fibrosis and Emphysema (CPFE): Analysis of the SPIROMICS Cohort
HOESTEREY, DANIEL , Kim, G.H.J., Lee, Jungmin , Pourzand, Lila , Oh, Andrea , Bateman, Lori A. , Cooper, C.B., Hansel, Nadia N. , Kim, V., Ortega, Victor E. , Paine, Robert , Peters, Stephen P. , Wang, J.M., Woodruff, Prescott G. , Abtin, F., Tashkin, Donald P. , Hoffman, Eric A. , Barr, R. Graham , Bowler, Russell P. , Cooper, C.B. , Couper, David , Curtis, Jeffrey L. , Dransfield, Mark T. , Drummond, Michael , Han, MeiLan King , Kaner, Robert J. , Krishnan, Jerry A , Martínez, Fernando J. , Reinhardt, Joseph M. , Wells, J. Michael , Goldin, Jonathan , Abtin, Fereidoun G. , Barjaktarević, Igor

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5118-A5118

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5118 Get It

Invasive Cardiopulmonary Exercise Testing Phenotypes of Chronic Thromboembolic Pulmonary Vascular Disease
Kirupaharan, Pradhab , Azar, J., Wang, Xiaofeng , Wang, Y., Tonelli, Adriano R. , Heresi, Gustavo A.

Mayo Clinic

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7367-A7367

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7367 Get It

Comparative Assessment of CO 2 Emissions in Various Delivery Methods of the Certain Critical Care Education Program
Zambrano, Claudia Castillo , Gajić, Ognjen, Wang, B.Y., Niven, Alexander S. , Gajic, Ognjen , Dong, Yue

Mayo Clinic

A39. EDUCATING THE EDUCATORS: ADVANCES IN CRITICAL CARE MEDICAL EDUCATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1509-A1509

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1509 Get It

Socioeconomic Deprivation Is Associated With Prevalence and Persistence of Airway Mucus Plugs in Patients With COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, R. San José , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A54. EXPLORING ASTHMA AND COPD: DIVERSE INSIGHTS FROM GLOBAL PERSPECTIVES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2110-A2110

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2110 Get It

Airway Mucus Plugging in Upper Versus Lower Lobes and Associations With Outcomes in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A29. WHAT IS YOUR DAMAGE? IMAGING-BASED PHENOTYPES OF COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1247-A1247

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1247 Get It

Multicenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma
Moinova, Helen , Verma, Suman, Dumot, John A. , Faulx, Michael , Iyer, Prasad G. , Canto, Marcia Irene , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanthi N. , Aklog, Lishan , Willis, Joseph , Markowitz, Sanford D. , Chak, Amitabh , Moinova, Helen R , Dumot, John , Willis, Joseph E

Mayo Clinic

American Journal of Gastroenterology | April 30, 2024 | Volume: 119 | Issue: 11 | Pages: 2206-2214

10.14309/ajg.0000000000002850 | PMID 38686933 Get It

INTRODUCTION: Preliminary data suggest that an encapsulated balloon (EsoCheck), coupled with a 2 methylated DNA biomarker panel (EsoGuard), detects Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) with high accuracy. The initial assay requires sample freezing upon collection. The purpose of this study was to assess a next-generation EsoCheck sampling device and EsoGuard assay in a much-enlarged multicenter study clinically enhanced by using a Clinical Laboratory Improvement Amendments of 1988-compliant assay and samples maintained at room temperature. METHODS: Cases with nondysplastic BE (NDBE), dysplastic BE (indefinite for dysplasia, low-grade dysplasia, high-grade dysplasia), EAC, junctional adenocarcinoma, plus endoscopy controls without esophageal intestinal metaplasia, were prospectively enrolled. Medical assistants at 6 institutions delivered the encapsulated balloon per orally with inflation in the stomach. The inflated balloon sampled the distal 5 cm of the esophagus and then was deflated and retracted into the capsule, preventing sample contamination. EsoGuard bisulfite sequencing assayed levels of methylated vimentin and methylated cyclin A1. RESULTS: A total of 243 evaluable patients—88 cases (median age 68 years, 78% men, 92% White) and 155 controls (median age 57 years, 41% men, 88% White)—underwent adequate EsoCheck sampling. The mean procedural time was approximately 3 minutes. Cases included 31 with NDBE, 16 with indefinite for dysplasia/low-grade dysplasia, 23 with high-grade dysplasia, and 18 with EAC/junctional adenocarcinoma. Thirty-seven NDBE and dysplastic BE cases (53%) were short-segment BE (<3 cm). Overall sensitivity was 85% (95% confidence interval 0.78–0.93) and specificity was 85% (95% confidence interval 0.79–0.90). Sensitivity for NDBE was 84%. EsoCheck/EsoGuard detected 100% of cancers (n = 18). DISCUSSION: EsoCheck/EsoGuard demonstrated high sensitivity and specificity in detecting BE and BE-related neoplasia.
Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Innocenti, Federico , Diasio, Robert B. , Largiadèr, Carlo R. , Offer, Steven M. , Largiadèr, Carlo R , Offer, Steven M , Bouchonville, Kelly J. , Wang, Zhiquan , Stroka, Deborah

Mayo Clinic

No container title available | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.3.sa2 Get It

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Innocenti, Federico , Diasio, Robert B. , Bouchonville, Kelly J. , Wang, Zhiquan , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M.

Mayo Clinic

eLife | April 30, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075.3 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P &amp;lt; .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P &amp;lt; .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Defining primary refractory large B-cell lymphoma
Bock, Allison M. , Mwangi, Raphael , Wang, Yucai , Khurana, Arushi , Maurer, Matthew J. , Ayers, Amy , Cohen, Jonathon B. , Casulo, Carla , Lossos, Izidore S. , Reicks, Tanner W., Flowers, Christopher R. , Nowakowski, Grzegorz S. , Cohen, Jonathon B , Casulo, Carla , Lossos, Izidore S , Farooq, Umar , Reicks, Tanner, Witzig, T.E. , Cerhan, James R , Nastoupil, Loretta J , Maurer, Matthew , Wang, Yucai , Kahl, Brad S. , Martin, Peter, Ayyappan, Sabarish Ram , Habermann, Thomas M. , Witzig, Thomas E. , Cerhan, James R. , Nastoupil, Loretta J.

Mayo Clinic

Blood Advances | April 26, 2024 | Volume: 8 | Issue: 13 | Pages: 3402-3415

10.1182/bloodadvances.2024012760 | PMID 38669353 Get It

Abstract Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have “primary refractory disease.” However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we examined variation in the time to relapse used to define refractory status and association with survival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with validation in an independent multicenter cohort. Patients with newly diagnosed LBCL were enrolled in the Molecular Epidemiological Resource cohort (MER; N = 949) or the Lymphoma Epidemiology of Outcomes cohort (LEO; N = 2755) from September 2002 to May 2021. Primary refractory LBCL was defined as no response (stable disease [SD]) or progressive disease (PD) during, or by the end of, frontline (1L) IC (primary PD; PPD); partial response at end of treatment (EOT PR); or relapse within 3 to 12 months after achieving CR at EOT to 1L IC (early relapse). In the MER cohort, patients with PPD had inferior overall survival (OS; 2-year OS rate: 15% MER, 31% LEO) when compared with other subgroups considered in defining primary refractory disease, EOT PR (2-year OS rate: 38% MER, 50% LEO) and early relapse (2-year OS rate: 44% MER, 58% LEO). Among patients receiving 1L IC with curative intent, we identified that patients with PPD are the key subgroup with poor outcomes. We propose a definition of primary refractory LBCL as SD or PD during, or by the end of, 1L treatment.